Goodness Growth Holdings Announces First Quarter 2024 Results

 

Q1 2024 revenue of $21.1 million excluding discontinued operations and NY increased 44.5% year-over-year –

 

  – Submitted a substantial legal filing on May 2nd in the ongoing litigation with Verano –  

 

  – Company announces launch of Hi*AF and Boundary Waters branded beverages –  

 

MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today reported financial results for its first quarter ended March 31, 2024. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.

 

                                                         
  Summary of Key Financial Metrics     
  Three Months Ended
  March 31,
  US $ in millions   2024 2023 Variance
GAAP Revenue $24.1 $19.1 26.2%
Revenue (excluding discontinued operations & NY) $21.1 $14.6 44.5%
GAAP Gross Profit $12.2 $9.5 28.6%
  Gross Profit Margin    50.8   %    49.9   %    90 bps  
SG&A Expenses $7.1 $7.2 -1.5%
  SG&A Expenses (% of Sales)    29.3   %    37.5   %    880 bps  
Operating Income (Loss) $4.8 $0.4 1191.6%
  Operating Income Margin    19.8   %    1.9   %    1,780 bps  
EBITDA* $6.8 $1.4 370.5%
  EBITDA Margin    28.2   %    7.6   %    2,060 bps  
  * 1Q24 EBITDA includes a $1.3 million gain on Grown Rogue warrants which are marked to market at each period end  
    
 

  Management Commentary  

 

Chief Executive Officer Josh Rosen commented, "Our first quarter results reflect a continuation of the trends we observed during the fourth quarter, with continued improvements in operating and financial performance driven by the commencement of adult-use sales in Maryland in July 2023. In 2024, our teams remain focused on executing the key tenets of our CREAM & Fire strategy. As it relates to our divestiture process in New York, we continue to make progress with Ace Venture Enterprises and are also anticipating receiving approval to sell wholesale into the adult-use market shortly. With a short-term extension completed last week, we are also close to finalizing a longer-term extension with our senior secured lender, which has been supported by our progress with the New York divestiture and improved operating performance; that said our overall credit metrics have significant room for improvement and we continue to feel the pain of what we believe was the wrongful termination of our merger agreement with Verano."

 

Amber Shimpa, President and CEO of Vireo Health of Minnesota, commented, "Our operational key performance indicators continued to show strong improvements during the first quarter, and we continue to demonstrate market outperformance in Maryland's adult-use market. This past April 20 th holiday we were also pleased to build upon the success of our Hi*AF brand of vapes in Maryland with the launch our new Hi*AF and Boundary Waters branded cannabis beverages in our home market in Minnesota. We believe these new product introductions will help drive brand awareness ahead of the launch of adult-use sales in 2025, and we are looking forward to sharing additional details regarding our plans to prepare for Minnesota's adult-use launch later this year."

 
                                               
  Core Market KPIs   1     
    
  Three Months Ended
  US $ in millions   March 31,
  2024 2023 Variance
Total Flower Harvested (lbs) 2,295 1,720 33.4%
  % "A" Flower   2    50.6   %    47.9   %    270 bps  
Total Retail Revenue $17.8 $13.1 36.2%
Same Store Sales Growth - - 36.2%
  Minnesota    -    -    2.4   %  
  Maryland    -    -    190.8   %  
Total Wholesale Revenue $3.4 $1.6 114.4%
  1   Core Markets refer to the Company's operations in Maryland and Minnesota.  
  2   "A Flower" refers to produced biomass that meet the Company's highest internal standards for flower quality, size, and appearance.   
 
 
 

  Other Events  

 

On April 1, 2024, the Company announced that it has executed a binding term sheet with ACE Venture Enterprises, Inc. ("Ace"), whereby Ace will acquire Goodness Growth Holdings subsidiary, Vireo Health of New York, pending regulatory approval. Terms of the transaction include a purchase price between $3.0 and $5.0 million for Vireo Health of New York's licenses, inventory and assets, an investment of $20.0 million from Ace for the development of the Johnstown, NY cannabis cultivation and manufacturing campus, and Ace's assumption of the Johnstown lease agreement with Innovative Industrial Properties. The parties also committed to a collaborative advisory agreement that retains Goodness Growth's management and compliance oversight in return for an approximate 15 percent share of net profits.

 

On May 1, 2024, the Company announced several leadership and corporate updates related to the day-to-day management of its business. Josh Rosen, who had served as Interim CEO since February of 2023, was appointed as Chief Executive Officer, effective immediately. The Company also provided updates regarding additional recent key personnel hires, details regarding a temporary extension of its credit agreement with its senior secured lender until June 14, 2024, and its planned name change to Vireo during the second quarter of 2024.

 

On May 2, 2024, the Company announced that it filed an application with the Supreme Court of British Columbia for summary determination in its ongoing litigation with Verano Holdings, Inc. ("Verano"). Goodness Growth is seeking damages of US $860.9 million from Verano, as well as other costs and legal fees, based on Verano's breach of contract and of its duty of good faith and honest performance. While the Company's filing of its application for summary determination reflects its belief that Verano's defense against its claims of unlawful conduct is without merit, Goodness Growth can make no assurances regarding the expected timeframe to resolve this litigation, or its ability to recover damages from Verano.

 

  Balance Sheet and Liquidity  

 

As of March 31, 2024, total current assets were $147.2 million, including cash on hand of $12.6 million. Total current liabilities were $184.2 million, including $88.4 million in liabilities held for sale related to the Company's businesses in the State of New York. As of March 31, 2024, the Company had a total of 234,937,843 shares outstanding on the treasury method basis.

 

  Launch of Hi*AF & Boundary Waters Branded Beverages  

 

On April 20, 2024, the Company launched its new lines of Hi*AF and Boundary Waters low-dose hemp-derived THC beverages in its home market of Minnesota. The Company's launch of beverages represents the culmination of months of work to establish a position in a growing sales channel within Minnesota with potential for expansion across the United States.

 

Amber Shimpa commented, "In a very short timeframe, Minnesota has established a robust market for low-dose THC product consumption both onsite in many bars, restaurants, and breweries, as well as at retail points of sale throughout the State. We have had a front row seat to this evolution and believe beverages represent an important sales channel that will drive greater adoption of cannabis consumption with new consumers as the industry continues to mature. Our beverages strategy reflects a capital light, low risk entry into this market with low-dose hemp-derived THC beverage products, and provides an attractive marketing opportunity to seed our brands ahead of the launch of adult-use sales in 2025."

 

  Conference Call and Webcast Information  

 

Goodness Growth management will host a conference call with research analysts today, May 7, 2024, at 4:30 p.m. ET (3:30 p.m. CT) to discuss its financial results for its first quarter ended March 31, 2024. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

 

A live audio webcast of this event will also be available in the Events & Presentations section of the Company's Investor Relations website and via the following link:
https://events.q4inc.com/attendee/586704075 .

 

  About Vireo & Goodness Growth  

 

Vireo (Goodness Growth) was founded as a pioneer in medical cannabis in 2014 and sustained with an entrepreneurial drive that fuels our ongoing commitment to serve and delight our key stakeholders, most notably our customers, our employees, our shareholders, our industry collaborators, and the communities in which we live and operate. We work every day to get better and our team prioritizes 1) empowering and supporting strong local market leaders and 2) strategic, prudent capital and human resource allocation. For more information, please visit www.vireohealth.com .

 

  Additional Information  

 

Additional information relating to the Company's first quarter 2024 results will be available on EDGAR and SEDAR later today. Goodness Growth refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures.

 

  Contact Information  

 
    
  Investor Inquiries:  
Sam Gibbons
Investor Relations  
investor@vireohealth.com
(612) 314-8995
  Media Inquiries:  
Amanda Hutcheson
Senior Manager, Communications  
amandahutcheson@goodnessgrowth.com
(919) 815-1476
  
 

  Forward-Looking Statement Disclosure  

 

This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "should," "believe," "estimate," "would," "looking forward," "may," "continue," "expect," "expected," "will," "likely," "subject to," "transformation," and "pending," variations of such words and phrases, or any statements or clauses containing verbs in any future tense. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue, EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

 

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company's ability to meet the demand for flower in Minnesota; risk of failure in the lawsuit with Verano and the cost of that litigation; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company's Form 10-K for the year ended December 31, 2023, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com .

 

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

 

  Supplemental Information  

 

The financial information reported in this news release is based on unaudited financial statements for the first fiscal quarter ended March 31, 2024, and March 31, 2023. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company's audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company's audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

 
                                                                                                                                                                                                                                                                                                                  
      
  GOODNESS GROWTH HOLDINGS, INC.       
  CONSOLIDATED BALANCE SHEETS AS OF 3/31/2024 AND 12/31/2023  
  (Amounts Expressed in United States Dollars, Unaudited and Condensed)  
   March 31,     December 31,  
   2024     2023  
  Assets       
Current assets:      
Cash $ 12,603,903    $ 15,964,665  
Accounts receivable, net of allowance for doubtful accounts of $254,961 and $453,860, respectively   2,753,673     3,086,640  
Income tax receivable   12,102,916     12,278,119  
Inventory   19,357,250     19,285,870  
Prepayments and other current assets   1,046,127     1,336,234  
Notes receivable, current   3,750,000     3,750,000  
Warrants held   3,265,231     1,937,352  
Assets Held for Sale   92,297,445     91,213,271  
Total current assets   147,176,545     148,852,151  
Property and equipment, net   23,541,445     23,291,183  
Operating lease, right-of-use asset   11,118,882     2,018,163  
Intangible assets, net   8,513,765     8,718,577  
Deposits   533,745     383,645  
Total assets $ 190,884,382    $ 183,263,719  
  Liabilities       
Current liabilities      
Accounts Payable and Accrued liabilities $ 7,970,158    $ 7,674,389  
Long-Term debt, current portion   60,896,288     60,220,535  
Right of use liability   882,457     890,013  
Uncertain tax liability   26,116,000     22,356,000  
Liabilities held for sale   88,373,080     88,326,323  
Total current liabilities   184,237,983     179,467,260  
Right-of-use liability   19,635,409     10,543,934  
Other long-term liabilities   176,257     155,917  
Convertible debt, net   9,410,053     9,140,257  
Total liabilities $ 213,459,702     199,307,368  
  Stockholders' equity (deficiency)       
Subordinate Voting Shares ($- par value, unlimited shares authorized; 111,041,230 shares issued and outstanding at March 31, 2024 and 110,007,030 at December 31, 2023)      
Multiple Voting Shares ($- par value, unlimited shares authorized; 320,851 shares issued and outstanding at March 31, 2024 and 331,193 at December 31, 2023)      
Super Voting Shares ($- par value; unlimited shares authorized; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023)      
Additional Paid in Capital   187,564,192     187,384,403  
Accumulated deficit   (210,139,512 )    (203,428,052 )
Total stockholders' equity (deficiency) $ (22,575,320 )   $ (16,043,649 )
  Total liabilities and stockholders' equity (deficiency)   $ 190,884,382    $ 183,263,719  
      
 

 

 
                                                                                                                                                                                                                                                                                            
  GOODNESS GROWTH HOLDINGS, INC.        
  CONSOLIDATED STATEMENTS OF OPERATIONS     
  THREE MONTHS ENDED MARCH 31, 2024 AND 2023     
  (Amounts Expressed in United States Dollars, Unaudited and Condensed)     
      Three Months Ended  
    March 31,  
      2024       2023  
  Revenue    $ 24,087,315    $ 19,088,423  
  Cost of sales        
Product costs    12,146,888     9,578,211  
Inventory valuation adjustments    (304,000 )    (10,000 )
Gross profit    12,244,427     9,520,212  
  Operating expenses:        
Selling, general and administrative    7,051,613     7,156,835  
Stock-based compensation expenses    179,789     1,675,594  
Depreciation    73,547     159,511  
Amortization    180,034     159,766  
Total operating expenses    7,484,983     9,151,706  
       
  Gain (loss) from operations     4,759,444     368,506  
       
  Other income (expense):        
Impairment of long-lived assets       
Gain (loss) on disposal of assets    (120,856 )    
Gain (loss) on sale of property and equipment       
Interest expenses, net    (8,722,637 )    (7,134,789 )
Other income (expenses)    1,317,589     22,313  
Other income (expenses), net    (7,525,904 )    (7,112,476 )
       
Loss before income taxes    (2,766,460 )    (6,743,970 )
       
Current income tax expenses    (3,945,000 )    (1,725,000 )
Deferred income tax recoveries       63,000  
Net loss and comprehensive loss    (6,711,460 )    (8,405,970 )
Net loss per share - basic and diluted   $ (0.05 )   $ (0.07 )
Weighted average shares used in computation of net loss per share - basic & diluted    143,126,330     128,126,330  
       
 

 

 
                                                                                                                                                                                                                                                                                                                                                     
  GOODNESS GROWTH HOLDINGS, INC.  
  CONSOLIDATED STATEMENTS OF CASH FLOWS  
  THREE MONTHS ENDED MARCH 31, 2024 AND 2023  
  (Amounts Expressed in United States Dollars, Unaudited and Condensed)  
    March 31,  
      2024       2023  
  CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss   $ (6,711,460 )   $ (8,405,970 )
Adjustments to reconcile net loss to net cash used in operating activities:       
Inventory valuation adjustments    (304,000 )    (10,000 )
Depreciation    73,547     159,511  
Depreciation capitalized into inventory    560,180     734,087  
Non-cash operating lease expense    103,564     206,290  
Amortization of intangible assets    180,034     159,766  
Amortization of intangible assets capitalized into inventory    24,778     
Stock-based payments    179,789     1,675,594  
Warrants held    (1,327,879 )    
Interest Expense    2,015,889     1,398,848  
Impairment of long-lived assets       
Deferred income tax       (63,000 )
Accretion    52,815     394,573  
Loss (gain) on disposal of assets    120,856     
Change in operating assets and liabilities:      
Accounts Receivable    348,817     24,448  
Prepaid expenses    290,106     513,902  
Inventory    299,252     (1,230,547 )
Income taxes    175,203     1,807,364  
Uncertain tax position liabilities    3,760,000     
Accounts payable and accrued liabilities    174,340     (1,141,057 )
Changes in operating lease liabilities    (168,746 )    
Change in assets and liabilities held for sale    (1,037,417 )    (18,767 )
Net cash provided by (used in) operating activities    (1,190,332 )    (3,794,958 )
  CASH FLOWS FROM INVESTING ACTIVITIES        
PP&E Additions    (899,264 )    (197,827 )
Deposits    (150,100 )    (522,375 )
Net cash provided by (used in) investing activities    (1,049,364 )    (720,202 )
  CASH FLOWS FROM FINANCING ACTIVITIES        
Debt principal payments    (1,050,000 )    
Lease principal payments    (71,066 )    (288,574 )
Net cash provided by (used in) financing activities    (1,121,066 )    (288,574 )
Net change in cash    (3,360,762 )    (4,803,734 )
Cash, beginning of period    15,964,665     15,149,333  
Cash, end of period   $ 12,603,903    $ 10,345,599  
       
 

 

 
                                                                                                                                                                                                                                                                               
 
  GOODNESS GROWTH HOLDINGS, INC.  
STATE-BY-STATE REVENUE PERFORMANCE
  THREE MONTHS ENDED MARCH 31, 2024 AND 2023  
 
    Three Months Ended          
    March 31,          
    2024     2023     $ Change     % Change    
   Retail:               
MN   $ 10,977,089    $ 10,718,916    $ 258,173    2 %
NY    1,821,269     2,361,942     (540,673 )   (23 )%
NM       1,052,316     (1,052,316 )   (100 )%
MD    6,801,082     2,338,625     4,462,457    191 %
  Total Retail     $    19,599,440      $    16,471,799      $    3,127,641        19    %  
             
   Wholesale:               
MD    3,353,661     1,563,875     1,789,786    114 %
NY    1,134,214     1,052,749     81,465    8 %
  Total Wholesale     $    4,487,875      $    2,616,624      $    1,871,251        72    %  
             
  Total Revenue     $    24,087,315      $    19,088,423      $    4,998,892        26    %  
NY and NM Revenue   $ (2,955,483 )   $ (4,467,007 )   $ 1,511,524    (34 )%
  Total Revenue excluding NY and NM     $    21,131,832      $    14,621,416      $    6,510,416        45    %  
             
 

  Reconciliation of Non-GAAP Financial Measures  

 

Goodness Growth management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA). EBITDA is a non-GAAP measure and does not have a standardized definition under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

 
                                                                                              
       
  Reconciliation of Net Loss to EBITDA   1        
       
    Three Months Ended  
    March 31,  
    2024     2023  
  Net income (loss)    $ (6,711,460 )   $ (8,405,970 )
Interest expense, net    8,722,637     7,134,789  
Income taxes    3,945,000     1,662,000  
Depreciation & Amortization    253,581     319,277  
Depreciation included in cost of goods sold    584,958     734,087  
  EBITDA (non-GAAP)    $ 6,794,716    $ 1,444,183  
  1   1Q24 EBITDA includes a $1.3 million gain on Grown Rogue warrants which are marked to market at each period end  
       
 

 

 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

CNX:GDNS,GDNSF
The Conversation (0)
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.

The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.

The country’s Ministry of Public Health issued an order this week stating that cannabis only be sold with a medical prescription, effectively ending a short-lived era of liberal recreational access.

Keep reading...Show less
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.

Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will reach AU$3.73 billion in 2024 and grow at an annual rate of 3.22 percent, culminating in market volume worth AU$4.53 billion by 2029.

However, Australia’s cannabis industry is still young. Despite there being a strong case for a regulated market, which was outlined in a July 2024 report by the Penington Institute, recreational use is not legal and medical access remains limited and regulated.

Keep reading...Show less
Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve.

Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among younger users, and cannabis companies are adapting their offerings to meet shifting demand.

Meanwhile, regulatory uncertainty, particularly surrounding the future of the US Farm Bill and state-level restrictions on hemp-derived cannabinoids, continues to challenge the market.

Despite these headwinds, production data and long-term growth forecasts suggest the cannabis industry remains on a promising — albeit turbulent — path. Read on for more on key trends to watch in 2025.

Consumption methods evolving post-legalization

Shifts in consumer behavior are reshaping markets across the board, and the cannabis industry is no exception.

While smoking remains the dominant method of cannabis consumption, a recent report from the Centers for Disease Control and Prevention highlights the growing popularity of edibles, vaping and dabbing.

The report notes that vaping and dabbing are particularly pronounced among younger adults.

A separate study published by the American Medical Association and funded in part by the Canadian Institutes of Health Research also points to how product preferences have changed among Canadian users since legalization in 2018.


The study indicates that while the use of flower, cannabis concentrates, oil, tinctures and topicals has decreased during that time, the use of vape cartridges, edibles and beverages has increased.

Edibles and beverages were legalized in Canada in late 2019, and Truss Beverage was one of the first players to introduce cannabis-infused drinks. Truss was a joint venture formed by Molson Coors Canada (TSX:TPX.A,TSX:TPX.B) and HEXO, a cannabis company that has since been acquired by Tilray Brands (TSX:TLRY,NASDAQ:TLRY).

In early 2020, Tilray launched a lineup of confectionery, wellness products and beverages through its subsidiary, High Park; Canopy Growth (TSX:WEED,NASDAQ:CGC) made a similar move. These companies gradually brought their products to the US as more states legalized cannabis for medical and/or recreational use.

Today, established cannabis brands typically offer edibles and beverages alongside their other products. Organigram Global (TSX:OGI,NASDAQ:OGI) is one of the newest US entrants, with its April acquisition of Collective Project providing immediate access to the US hemp-derived THC beverage market.

Growing awareness of health and wellness, potentially amplified by the pandemic-led adoption of health trackers, appears to be making an impact on the alcoholic beverage market.

A 2023 Gallup poll reveals a two decade decline in alcohol consumption, particularly among younger adults, suggesting a shift towards more health-conscious lifestyles within this demographic.

Craft beer production declined by 4 percent year-on-year in 2024, according to data collected by the Brewers Association. This marked the largest drop in the industry's history, excluding the pandemic. For small, independent craft breweries, 2024 marked the third consecutive year of declining production. A drop in the number of operating small breweries last year provides further evidence of this trend, with 501 closures in 2024 versus 434 openings.

Challenges in the alcohol market extend beyond the brewing industry, with the New York Times recently reporting the closure of a handful of nightclubs facing decreased alcohol sales alongside rising insurance and rent costs.

Meanwhile, cannabis lounges have been popping up across the US for the last several years. As of early 2025, several states had legalized or were in the process of implementing regulations for cannabis consumption lounges.

Hemp market growth despite regulatory uncertainty

The burgeoning hemp industry is another segment of the expanding cannabis market.

The legalization of industrial hemp — defined as cannabis with a THC concentration of 0.3 percent or less — through the 2018 Farm Bill led to initial investment and optimistic projections for CBD wellness products and various industrial applications. The sector’s rapid evolution also brought the rise of hemp-derived intoxicating cannabinoids, creating a market that presented both opportunities and complexities for participants.

However, after an initial boom, a lack of infrastructure and clearly defined regulations for CBD, as well as state-level variations and market oversupply, ultimately contributed to a quick retraction.

2024 was a pivotal year for the US hemp industry, as the hemp-related provisions of the 2018 Farm Bill — originally set to expire in September 2023, but extended to December 31, 2024 — created an urgent need to address critical issues like THC limits and the regulation of novel hemp-derived cannabinoids. A major point of contention was the proposed shift from defining hemp based on Delta-9 THC concentration (0.3 percent or less) to “total THC,” which includes THCA.

This change had the potential to significantly impact farmers and processors, as many hemp varieties that are compliant under the Delta-9 THC rule could exceed the 0.3 percent limit when THCA is included.

Various bills and amendments were proposed in 2024 as part of the Farm Bill discussions, each with different approaches to regulating hemp. Separate regulatory frameworks for industrial hemp and hemp grown for cannabinoids were suggested, and many states took their own action, leading to a patchwork of regulations and even outright bans.

Despite challenges, data from the US Department of Agriculture suggests signs of recovery.

The department's annual National Hemp Report from 2024 points to an 18 percent increase in industrial hemp production value between 2022 and 2023, with output growth seen in specific sectors like floral (18 percent), fiber (133 percent) and seed hemp (414 percent). The 2025 report from the Department of Agriculture indicates further expansion, with notable increases observed in both acreage (up 64 percent from 2023) and value (46 percent).

The 2024 Farm Bill ultimately did not pass, and right now the hemp industry is operating under a temporary extension of the 2018 Farm Bill under the American Relief Act of 2025, signed into law on December 21, 2024.

The 2018 Farm Bill is now set to expire on September 30, 2025.

While analysts for Markets and Markets project that the North American hemp industry will grow at a CAGR of 22.4 percent and ultimately reach a valuation of US$30.24 billion by 2029, the future of the industry will be heavily influenced by the outcome of the ongoing Farm Bill discussions.

US cannabis legalization remains stalled

Although there is clear demand for cannabis products, the now-defunct rescheduling process in the US is likely to continue casting a shadow of uncertainty over the industry's long-term trajectory.

Legal and procedural delays, including allegations of improper conduct and bias within the US Drug Enforcement Administration (DEA), led to hearing cancellations, and the new administration of US President Donald Trump has brought leadership changes to key agencies like the DEA and the Department of Justice.

Terry Cole, who Trump nominated to be DEA administrator on February 11, has a history of opposing cannabis legalization in the country. Similarly, Pam Bondi, Trump’s pick to lead the justice department, staunchly opposed a movement to legalize medical cannabis during her tenure as Florida’s attorney general.

While there have been bipartisan efforts in Congress to end federal cannabis prohibition and establish regulations for eventual legalization, the DEA’s actions and statements indicate a potential stall or reversal of progress.

In addition to that, new research is adding complexity to the debate.

A study published in the American Journal of Psychiatry this past March highlights an association between the use of high-potency cannabis strains and increased risks of psychosis, a factor that may not have been fully considered by the Department of Health and Human Services. As stronger cannabis strains become more widely available, a reassessment of their potential health risks may be required.

Investor takeaway

While the cannabis industry holds promise for growth and innovation, investors must remain acutely aware of the regulatory uncertainties and market volatility that will undoubtedly shape its trajectory in the years to come.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Person touching a cannabis plant; Australia map in flag colours.

ASX Cannabis Stocks: 10 Biggest Companies

While Australia has yet to legalise all forms of cannabis, the country is a growing medical cannabis and hemp market, with many companies manufacturing, researching and exporting the plant-based product.

Medical cannabis was federally legalised in 2016, and the export of cannabis from Australia was legalised in 2018. As for recreational use, the only state to legalise recreational use and possession so far is the Australian Capital Territory, which did so in 2020, but it did not establish a regulated recreational cannabis market.

The country's medical cannabis market has been steadily expanding in size and scope. A Penington Institute report shows that Australians spent approximately AU$400 million on medicinal cannabis in the first half of 2024, 72 percent higher than the AU$234 million they spent over the entirety of 2022.

Keep reading...Show less
Cannabis leaves, gavel.

Cannabis Round-Up: Rescheduling Faces New Roadblocks, SAFER Banking Act Gets Another Look

February 2025 was characterized by an evolving legislative landscape and important financial updates from major players.

These developments underscore the complex and dynamic nature of the sector as it continues to navigate legal, financial, and regulatory challenges while experiencing ongoing growth and evolution.

Discussions around cannabis rescheduling, changes in federal agency leadership, state-level legalization efforts, and financial reports from key companies all contributed to a month of notable activity in the cannabis space.

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: Banking Reform and Rescheduling De-Prioritized as Trump Takes Office

As a new year began, the cannabis industry saw a range of impactful events in January.

Legal obstacles continued to impede progress on a once-promising attempt to reschedule cannabis in the US, and President Donald Trump's leadership choices for key agencies are diminishing hopes it can be accomplished.

Meanwhile, cannabis banking reform won't be discussed at Wednesday's (February 5) meeting of the Standing Senate Committee on Banking, Commerce and the Economy, and Congress seems in no rush to address it.

Keep reading...Show less

Latest Press Releases

Related News

×